FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2088798001> ?p ?o ?g. }

• W2088798001 endingPage "239" @default.
• W2088798001 startingPage "239" @default.
• W2088798001 abstract "Follicular lymphoma is predominantly managed as a chronic disease, with intermittent chemo/immunotherapy reserved for symptomatic progression. It is considered incurable with conventional treatments, and current therapeutic options are associated with significant toxicities that are especially limiting in older patients. Bortezomib (PS-341; Velcade(®)), a first-in-class drug targeting the proteolytic core subunit of the 26S proteasome, has emerged as a therapeutic alternative in follicular lymphoma, with promising preclinical data and efficacy in patients with other hematological malignancies. Several clinical trials were conducted with bortezomib for the treatment of non-Hodgkin's lymphoma. As a single agent, overall responses in follicular lymphoma varied greatly (16%-41%), with weekly bortezomib showing less neurotoxicity than twice-weekly regimens, but with concern about decreased responses. Combination with rituximab was projected to improve the efficacy of bortezomib, but this resulted in increased toxicities and questionable added benefit. Although the largest Phase III study in follicular lymphoma of bortezomib plus rituximab versus rituximab alone demonstrated a significant progression-free survival difference, the absolute difference was small (12.8 months versus 11 months). Combining bortezomib with established regimens, such as rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP), or rituximab-bendamustine also did not show definite benefit, and many of these studies did not meet their primary endpoint when bortezomib failed to improve responses or survival to the degree anticipated. In a disease where the goal of treatment is palliative and affected patients often have other medical and treatment-related comorbidities, decisions regarding therapies which carry risks of additional toxicities must be considered carefully. Conclusive evidence of the ability of bortezomib to improve patient outcomes meaningfully and to justify the added toxicity is lacking, but limitations in cross-trial comparisons are recognized. Large randomized trials and investigations of combinations with promising novel targeted agents will aid in determining the role of bortezomib, if any, in the future treatment of follicular lymphoma." @default.
• W2088798001 created "2016-06-24" @default.
• W2088798001 creator A5042332348 @default.
• W2088798001 creator A5086211539 @default.
• W2088798001 date "2012-03-01" @default.
• W2088798001 modified "2023-09-25" @default.
• W2088798001 title "Update on treatment of follicular non-Hodgkin’s lymphoma: focus on potential of bortezomib" @default.
• W2088798001 cites W1481714849 @default.
• W2088798001 cites W1575566517 @default.
• W2088798001 cites W1589631234 @default.
• W2088798001 cites W1938721925 @default.
• W2088798001 cites W1964175291 @default.
• W2088798001 cites W1965867669 @default.
• W2088798001 cites W1969582706 @default.
• W2088798001 cites W1970451442 @default.
• W2088798001 cites W1978345721 @default.
• W2088798001 cites W1980830373 @default.
• W2088798001 cites W1982790762 @default.
• W2088798001 cites W1985343909 @default.
• W2088798001 cites W1987378323 @default.
• W2088798001 cites W1988741527 @default.
• W2088798001 cites W1988855108 @default.
• W2088798001 cites W1989740966 @default.
• W2088798001 cites W1997869842 @default.
• W2088798001 cites W2010818204 @default.
• W2088798001 cites W2011046139 @default.
• W2088798001 cites W2019049627 @default.
• W2088798001 cites W2039034185 @default.
• W2088798001 cites W2042396314 @default.
• W2088798001 cites W2058468326 @default.
• W2088798001 cites W2061272096 @default.
• W2088798001 cites W2067530043 @default.
• W2088798001 cites W2067653691 @default.
• W2088798001 cites W2072252062 @default.
• W2088798001 cites W2092915615 @default.
• W2088798001 cites W2096617375 @default.
• W2088798001 cites W2098134963 @default.
• W2088798001 cites W2098422029 @default.
• W2088798001 cites W2100608938 @default.
• W2088798001 cites W2101141816 @default.
• W2088798001 cites W2105395943 @default.
• W2088798001 cites W2108063064 @default.
• W2088798001 cites W2116090592 @default.
• W2088798001 cites W2116573634 @default.
• W2088798001 cites W2117733789 @default.
• W2088798001 cites W2118820477 @default.
• W2088798001 cites W2119661337 @default.
• W2088798001 cites W2119680582 @default.
• W2088798001 cites W2120755425 @default.
• W2088798001 cites W2121239154 @default.
• W2088798001 cites W2122978754 @default.
• W2088798001 cites W2123235255 @default.
• W2088798001 cites W2131998596 @default.
• W2088798001 cites W2134902298 @default.
• W2088798001 cites W2136326451 @default.
• W2088798001 cites W2138077682 @default.
• W2088798001 cites W2138102966 @default.
• W2088798001 cites W2143471362 @default.
• W2088798001 cites W2146197981 @default.
• W2088798001 cites W2147422161 @default.
• W2088798001 cites W2150280279 @default.
• W2088798001 cites W2151458137 @default.
• W2088798001 cites W2156813481 @default.
• W2088798001 cites W2158734599 @default.
• W2088798001 cites W2163498786 @default.
• W2088798001 cites W2166043738 @default.
• W2088798001 cites W2167355583 @default.
• W2088798001 cites W2168926834 @default.
• W2088798001 cites W2169183166 @default.
• W2088798001 cites W2169578616 @default.
• W2088798001 cites W2172122039 @default.
• W2088798001 cites W2203017689 @default.
• W2088798001 cites W2262413988 @default.
• W2088798001 cites W2341289653 @default.
• W2088798001 cites W2562994716 @default.
• W2088798001 cites W2593902338 @default.
• W2088798001 cites W2786429208 @default.
• W2088798001 cites W2107015511 @default.
• W2088798001 doi "https://doi.org/10.2147/ppa.s23241" @default.
• W2088798001 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3333814" @default.
• W2088798001 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22536060" @default.
• W2088798001 hasPublicationYear "2012" @default.
• W2088798001 type Work @default.
• W2088798001 sameAs 2088798001 @default.
• W2088798001 citedByCount "0" @default.
• W2088798001 crossrefType "journal-article" @default.
• W2088798001 hasAuthorship W2088798001A5042332348 @default.
• W2088798001 hasAuthorship W2088798001A5086211539 @default.
• W2088798001 hasBestOaLocation W20887980011 @default.
• W2088798001 hasConcept C126322002 @default.
• W2088798001 hasConcept C143998085 @default.
• W2088798001 hasConcept C2776364478 @default.
• W2088798001 hasConcept C2776694085 @default.
• W2088798001 hasConcept C2776755627 @default.
• W2088798001 hasConcept C2777058707 @default.
• W2088798001 hasConcept C2777478702 @default.
• W2088798001 hasConcept C2778476748 @default.
• W2088798001 hasConcept C2778720950 @default.

• next